RESUMO
PURPOSE: It has been reported that the combination therapy of imatinib mesylate, a tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, is associated with remarkable antitumor activity in patients with recurrent glioblastoma multiforme. However, the mechanism of the added activity of hydroxyurea to imatinib is not known. The purpose of this study was to investigate in vitro, whether hydroxyurea could enhance the central nervous system penetration of imatinib, by inhibition of the ATP-dependent transporter proteins P-glycoprotein (ABCB1; MDR1; Pgp) and Breast Cancer Resistance Protein (ABCG2; BCRP), or by inhibition of cytochrome P450 3A (CYP3A) metabolism of imatinib. METHODS: The effect of hydroxyurea on the Pgp and BCRP mediated transport of imatinib was investigated by the sulforhodamine-B (SRB) drug cytotoxicity assay and transepithelial transport assay. In vitro biotransformation studies with supersomes expressing human CYP3A4 were performed to investigate whether hydroxyurea inhibited CYP3A4. RESULTS: In both in vitro cytotoxicity and transport assays, hydroxyurea did not affect Pgp and BCRP mediated transport of imatinib. In a biotransformation assay, hydroxyurea had no influence on the metabolic degradation of imatinib either. CONCLUSION: The results indicate that hydroxyurea does not interact with imatinib by inhibition of Pgp and BCRP mediated transport or by CYP3A4 mediated metabolism of imatinib.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/farmacologia , Transportadores de Cassetes de Ligação de ATP/farmacologia , Transporte Biológico Ativo/efeitos dos fármacos , Citocromo P-450 CYP3A/metabolismo , Hidroxiureia/farmacologia , Proteínas de Neoplasias/farmacologia , Piperazinas/metabolismo , Pirimidinas/metabolismo , Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP , Animais , Benzamidas , Linhagem Celular , Cães , Humanos , Mesilato de Imatinib , CamundongosRESUMO
This study was performed to test the hypothesis that conferring multiple drug resistance reduces cell susceptibility to irradiation and iron-stimulated lipid peroxidation. Multidrug resistant (PN1A) and parental drug sensitive (PSI-2) cell lines were exposed to ADP-Fe or Ascorbate-Fe complexes at 37 degrees C and to irradiation. Lipid peroxidation was estimated by the TBA test, whereas x-ray effect was estimated by clonogenic assay. Cell glutathione-S-transferase (GST), total and Se-dependent glutathione peroxidase (GSH-Px) activities, and glutathione and vitamin E were measured. PN1A produced more peroxides than PSI-2 after exposure to iron complexes and formed fewer colonies after irradiation. Higher activities of GST and total and Se-GSH-Px were observed in PN1A. Vitamin E and total glutathione did not differ in the two cell subclones. These data show that the induction of the mdr1 phenotype by transfection of mdr1 gene in 3T3 cells increases susceptibility to irradiation and iron stimulated lipid peroxidation.
Assuntos
Resistência a Múltiplos Medicamentos/genética , Peroxidação de Lipídeos/fisiologia , Tolerância a Radiação/genética , Transfecção , Células 3T3 , Animais , Radicais Livres , Camundongos , FenótipoRESUMO
BACKGROUND: In 1998, when data of a meta-analysis on tamoxifen in the treatment of hepatocellular carcinoma (HCC) had suggested a little advantage for this treatment, we published the results of a multicenter randomised controlled trial, that showed no survival benefit for tamoxifen vs. control. Here we report an updated analysis of the study results 4.5 years after the closure of enrollment. METHODS: The study had a planned sample size of 480 patients. Patients with any stage HCC were eligible, irrespective of locoregional treatment. Tamoxifen was given orally, 40 mg/die, from randomisation until death. RESULTS: 496 patients were randomised by 30 Institutions from January 1995 to January 1997. Information was available for 477 patients. As of July 2001, 374 deaths (78%) were recorded, and median survival times were 16 and 15 months (p=0.54), in the control and tamoxifen arm. Data were further analysed separately for advanced patients and for those eligible to potentially curative locoregional treatments: relative hazard of death for patients receiving tamoxifen was equal to 0.98 (95% CI 0.76-1.25) for the former group and 1.38 (95% CI 0.95-2.01) for the latter. The prognostic score recently devised by our group (CLIP score) was, as expected, strictly correlated (p<0.0001) to the locoregional treatment received and strongly correlated with prognosis. CONCLUSIONS: the update of the present study confirms that tamoxifen is not effective in prolonging survivals, both in advanced patients and in those potentially curable and that the CLIP score is able to predict prognosis.
Assuntos
Carcinoma Hepatocelular/tratamento farmacológico , Moduladores de Receptor Estrogênico/uso terapêutico , Neoplasias Hepáticas/tratamento farmacológico , Tamoxifeno/uso terapêutico , Carcinoma Hepatocelular/mortalidade , Feminino , Humanos , Neoplasias Hepáticas/mortalidade , MasculinoRESUMO
1. Haeme oxygenase (HO) is an enzyme mainly localized in the smooth endoplasmic reticulum and involved in haeme degradation and in the generation of carbon monoxide (CO). Here we investigate (1) whether the inducible isoform of HO (HO-1) is expressed in the isolated heart of the guinea-pig and (2) the functional significance of HO-1 on the response to antigen in isolated hearts taken from actively sensitized guinea-pigs. 2. Both the HO-1 expression and activity are consistently increased in hearts from guinea-pigs pretreated with hemin, an HO-1 inducer (4 mg kg(-1) i.p., 18 h before antigen challenge). The administration of the HO-1 inhibitor zinc-protoporphyrin IX (ZnPP-IX, 50 micromol kg(-1), i.p., 6 h before hemin) abolished the increase of both the HO-1 expression and activity. 3. In vitro challenge with the specific antigen of hearts from actively sensitized animals evokes a positive inotropic and chronotropic effect, a coronary constriction followed by dilation and an increase in the amount of histamine in the perfusates. In hearts from hemin-pretreated animals, antigen challenge did not modify the heart rate and the force of contraction; the coronary outflow was significantly increased and a diminution of the release of histamine was observed. The patterns of cardiac anaphylaxis were fully restored in hearts from animals treated with ZnPP-IX 6 h before hemin. 4. In isolated hearts perfused with a Tyrode solution gassed with 100% CO for 5 min and successively reoxygenated, the response to antigen was similar to that observed in hearts from hemin-pretreated animals. 5. Pretreatment with hemin or the exposure to exogenous CO were linked to an increase in cardiac cyclic GMP levels and to a decrease of tissue Ca(2+) levels. 6. The study demonstrates that overexpression of HO-1 inhibits cardiac anaphylaxis through the generation of CO which, in turn, decreases the release of histamine through a cyclic GMP- and Ca(2+)-dependent mechanism.
Assuntos
Heme Oxigenase (Desciclizante)/metabolismo , Miocárdio/enzimologia , Anafilaxia/enzimologia , Animais , Western Blotting , Cálcio/metabolismo , Monóxido de Carbono/metabolismo , Monóxido de Carbono/fisiologia , Circulação Coronária , GMP Cíclico/metabolismo , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/farmacologia , Cobaias , Coração/efeitos dos fármacos , Coração/fisiologia , Frequência Cardíaca , Heme Oxigenase (Desciclizante)/antagonistas & inibidores , Heme Oxigenase-1 , Hemina/farmacologia , Liberação de Histamina , Imunização Passiva , Injeções Intraperitoneais , Masculino , Contração Miocárdica , Técnicas de Cultura de Órgãos , Perfusão , Protoporfirinas/administração & dosagem , Protoporfirinas/farmacologiaRESUMO
Carbon monoxide (CO) is a signaling gas produced intracellularly by heme oxygenase (HO) enzymes using heme as a substrate. During heme breakdown, HO-1 and HO-2 release CO, biliverdin, and Fe(2+). In this study, we investigated the effects of manipulation of the HO-1 system in an in vivo model of focal ischemia-reperfusion (FIR) in the rat heart. Male Wistar albino rats, under general anesthesia and artificial ventilation, underwent thoracotomy, the pericardium was opened, and a silk suture was placed around the left descending coronary artery; ischemia was induced by tightening the suture and was monitored for 30 min. Subsequently, the ligature was released to allow reperfusion lasting for 60 min. The first group of rats was sham operated and injected intraperitoneally (i.p.) with saline. The second group underwent FIR. The third group was treated ip 18 hr before FIR with hemin (4 mg/kg). The fourth group was pretreated ip 24 hr before FIR and 6 hr before hemin with zinc protoporphyrin IX (ZnPP-IX, 50 microg/kg). Specimens of the left ventricle were taken for determination of HO expression and activity, infarct size, malonyldialdehyde (MDA) production, and tissue calcium content. FIR led to a significant increase in the generation of MDA and notably raised tissue calcium levels. Induction of HO-1 by hemin significantly decreased infarct size, incidence of reperfusion arrhythmias, MDA generation, and calcium overload induced by FIR. These effects were prevented by the HO-1 inhibitor ZnPP-IX. The present experiments show that the concerted actions of CO, iron, and biliverdin/bilirubin modulate the FIR-induced myocardial injury.
Assuntos
Heme Oxigenase (Desciclizante)/metabolismo , Miocárdio/metabolismo , Traumatismo por Reperfusão/metabolismo , Animais , Cálcio/metabolismo , Heme Oxigenase-1 , Hemina/metabolismo , Hemina/farmacologia , Masculino , Malondialdeído/metabolismo , Miocárdio/patologia , Protoporfirinas/metabolismo , Ratos , Ratos Wistar , Traumatismo por Reperfusão/patologiaRESUMO
We have previously shown that efflux of cytotoxic drugs from multidrug resistant (MDR) cell lines can be quantitated at the single cell level using a sensitive fluorescence microscopy technique. Based on the structure of compounds which inhibited the efflux of Rhodamine-123 (Rho-123) using this methodology, we hypothesized that the antiemetic, antihistaminic agent benzquinamide (BZQ) would interfere with P-glycoprotein (P-gp) mediated drug transport and potentiate the effects of anticancer agents in MDR cell lines. We show that BZQ interferes with P-gp mediated drug efflux and increases drug accumulation in MDR cells using Rho-123 as a fluorescent probe. BZQ increases the cytotoxicity of chemotherapeutic agents to both human and hamster MDR cell lines in vitro. A slight increase in cytotoxicity to chemotherapeutic agents is also observed in the parental cell lines with BZQ. BZQ increases [3H]daunorubicin accumulation and inhibits the binding of [125I]iodoaryl azidoprazosin to the P-gp in MDR cells. BZQ is a new agent to increase the cytotoxic effects of anticancer agents in MDR cells and may ultimately prove useful as an adjunct in cancer chemotherapy.
Assuntos
Antineoplásicos/farmacologia , Glicoproteínas de Membrana/antagonistas & inibidores , Proteínas de Neoplasias/antagonistas & inibidores , Quinolizinas/farmacologia , Membro 1 da Subfamília B de Cassetes de Ligação de ATP , Marcadores de Afinidade , Animais , Antineoplásicos/farmacocinética , Sobrevivência Celular/efeitos dos fármacos , Cricetinae , Resistência a Medicamentos , Sinergismo Farmacológico , Humanos , Glicoproteínas de Membrana/metabolismo , Camundongos , Microscopia de Fluorescência , Fenótipo , Ligação Proteica/efeitos dos fármacos , Rodamina 123 , Rodaminas/farmacocinética , Células Tumorais CultivadasRESUMO
BACKGROUND: Hepatocarcinoma is one of the most common malignant tumours world-wide with poor prognosis. Treatment of locally advanced hepatocarcinoma is still controversial. Transcatheter arterial (chemo-)embolisation of hepatocarcinoma are widely used methods but some aspects regarding their use and usefulness have not yet been clarified. Systemic remedies have not yet been proven to affect patient survival. AIMS: To determine if intra-arterial chemotherapy with 5-flurouracil and folinic acid in locally advanced hepatocarcinoma is a viable alternative to existing therapies. PATIENTS: Twenty-four inoperable consecutive patients with locally advanced hepatocarcinoma were enrolled. They all underwent intra-arterial chemotherapy via a surgically implanted port-a-cath, and folinic acid (100 mg/m2) and 5-flurouracil (up to 550 mg/m2) were administered with a 1-week or a 2-week schedule. RESULTS: Nineteen patients completed the study: 2 showed a complete positive response, 11 a partial response, 6 stable disease, while 4 showed a disease progression. Median survival time was 19 (range 4-85) months. Child A patients showed a significant longer survival. CONCLUSIONS: Intra-arterial chemotherapy using folinic acid and 5-flurouracil may be useful in the treatment of locally advanced hepatocarcinoma in cirrhotic patients even in the presence of thrombosis. This treatment could be also useful in comparing transarterial chemoembolisation to a curative treatment.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Hepatocelular/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Carcinoma Hepatocelular/mortalidade , Feminino , Fluoruracila/administração & dosagem , Humanos , Injeções Intra-Arteriais , Leucovorina/administração & dosagem , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Análise de Sobrevida , Taxa de Sobrevida , Resultado do TratamentoRESUMO
Fifty patients with various types of liver disease and twenty-one healthy subjects were examined for lipoperoxidation in vivo by gaschromatographic assay of volatile hydrocarbons (ethane, ethylene, propane, n-butane, n-pentane) in breath gases. In 15 patients with alcoholic cirrhosis the amount of expired pentane was greater than in all the other groups examined. No significant increase of exhaled ethane, in contrast, was detected in the same patients. These results seem to indicate that pentane is a more sensitive index than ethane for ethanol-induced lipoperoxidation. This simple and non-invasive method opens up promising new opportunities for clarifying in humans, the role of lipoperoxidation in ethanol-induced liver damage, as well as in other chronic liver disease.
Assuntos
Hidrocarbonetos/análise , Peróxidos Lipídicos/metabolismo , Hepatopatias/metabolismo , Adulto , Testes Respiratórios , Cromatografia Gasosa , Doença Crônica , Feminino , Humanos , Hepatopatias Alcoólicas/metabolismo , Masculino , Pessoa de Meia-IdadeRESUMO
The present review firstly gives some details regarding nosological approach to the cholestatic syndrome. In addition, different steps are considered, identifying 12 possible metabolic defects responsible for determining a cholestatic syndrome either in man or in experimental conditions. Eleven defects out of these 12 steps should be considered related to the structure and function of the hepatocyte, whereas the twelfth one, which comprises 3 different sub-groups, is based on a mechanical obstructive mechanism, localized exclusively into the liver parenchyma, thus resembling the other ones included in the chapter of intrahepatic cholestasis.
Assuntos
Colestase Intra-Hepática/etiologia , Bile/metabolismo , Colestase Intra-Hepática/fisiopatologia , Humanos , Fígado/fisiopatologia , Fígado/ultraestruturaRESUMO
The role of hepatitis B virus (HBV) and hepatitis C virus (HCV) as a major cause of chronic liver disease is now accepted worldwide. This study was aimed at evaluating the natural history of the disease in patients with virus-induced chronic active hepatitis or cirrhosis, and the influence played by age, sex and etiology, liver function tests and by the occurrence of different complications. We retrospectively examined the clinical records of 506 inpatients: 194 were affected by chronic active hepatitis (125 males, 69 females, mean age 45 +/- 11 years, 146 HCV- and 48 HBV-related), and 312 by cirrhosis without clinical evidence of portal hypertension (178 males, 134 females, mean age 53 +/- 9 years, 249 HCV- and 63 HBV-related). The occurrence of cirrhosis in the chronic active hepatitis group was then calculated, together with the occurrence of complications and the cumulative mortality rate of established cirrhosis. During follow-up 93 patients with chronic hepatitis developed cirrhosis. The cumulative probability of developing cirrhosis in this group was 6.64% at 5 years, 56.1% at 10 years and 86.8% at 15 years. These patients were therefore included in the cirrhosis group for the final analysis, so that a total of 405 cirrhotic patients were evaluated: these patients had a cumulative survival rate of 99.1% at 5, 76.8% at 10 and 49.4% at 15 years. Comparing the age-adjusted death rate of our patients with the general Italian population, we observed that in patients with liver cirrhosis it was 3.14 and 2.84 times higher in men and women, respectively. Bilirubin was an independent indicator of survival. Several complications, such as esophageal varices, ascites, jaundice, hemorrhage, hepatic encephalopathy and hepatocellular carcinoma significantly reduced the survival rate and were indicated as major complications, while thrombocytopenia, cholelithiasis and diabetes did not affect survival and thus were called minor complications. Incidence of hepatocellular carcinoma was very high especially in males, without correlation with etiology. In conclusion, the progression of virus-induced chronic active hepatitis to cirrhosis is not influenced by sex and etiology. Similarly, the different etiology does not modify the natural history of cirrhosis while the occurrence of one or more major complications significantly shortens survival. The longer survival rate observed in patients with cirrhosis included in this study is probably due to the selective inclusion of patients with early disease and no evidence of portal hypertension.
Assuntos
Hepatite Viral Humana/complicações , Cirrose Hepática/complicações , Cirrose Hepática/virologia , Adulto , Ascite/etiologia , Carcinoma Hepatocelular/etiologia , Varizes Esofágicas e Gástricas/etiologia , Feminino , Hemorragia Gastrointestinal/etiologia , Encefalopatia Hepática/etiologia , Humanos , Icterícia/etiologia , Cirrose Hepática/mortalidade , Cirrose Hepática/fisiopatologia , Neoplasias Hepáticas/etiologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Análise de SobrevidaAssuntos
Inibidores da Angiogênese/uso terapêutico , Carcinoma Hepatocelular/tratamento farmacológico , Neoplasias Hepáticas/tratamento farmacológico , Antineoplásicos Hormonais/administração & dosagem , Antineoplásicos Hormonais/uso terapêutico , Carcinoma Hepatocelular/irrigação sanguínea , Carcinoma Hepatocelular/metabolismo , Fator 2 de Crescimento de Fibroblastos/metabolismo , Fator de Crescimento de Hepatócito/metabolismo , Humanos , Interleucina-2/administração & dosagem , Interleucina-2/uso terapêutico , Neoplasias Hepáticas/irrigação sanguínea , Neoplasias Hepáticas/metabolismo , Megestrol/administração & dosagem , Megestrol/uso terapêutico , Talidomida/administração & dosagem , Talidomida/uso terapêutico , Resultado do Tratamento , Fator A de Crescimento do Endotélio Vascular/metabolismoAssuntos
Hepatopatias/tratamento farmacológico , S-Adenosilmetionina/uso terapêutico , Adulto , Idoso , Doença Crônica , Avaliação de Medicamentos , Fígado Gorduroso/tratamento farmacológico , Hepatite/tratamento farmacológico , Humanos , Cirrose Hepática/tratamento farmacológico , Testes de Função Hepática , Pessoa de Meia-IdadeAssuntos
Hepatopatias Alcoólicas/epidemiologia , Adolescente , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Fígado Gorduroso Alcoólico/epidemiologia , Feminino , Hepatite Alcoólica/epidemiologia , Humanos , Lactente , Itália , Cirrose Hepática Alcoólica/epidemiologia , Masculino , Pessoa de Meia-Idade , Ocupações , Fatores SexuaisRESUMO
The overall survival for patients with metastatic melanoma is very poor, with a median survival of 8.5 months. In this Phase II trial, we assessed the efficacy, safety, and tolerability of a sequential biochemotherapy schedule, using dacarbazine as antiblastic agent and immunomodulant doses of interleukin-2 and interferon-alfa. Thirty-one eligible patients with metastatic melanoma received dacarbazine IV as antiblastic therapy and interluekin-2, plus interferon-alfa SC as sequential immunotherapy, for 6 months. Responding and nonprogressing patients were subsequently maintained on immunotherapy treatment for further 6 months. Twenty-nine patients had an adequate trial, and were assessable for both response and toxicities, with a median follow-up of 49 months. The overall response rate was 52 percent (3 CR and 12 PR), SD was 8 (27 percent) and PD were achieved in 6 patients (21 percent). The median survival duration of responders was 28 months, significantly longer (p < 0.001) than the 16 months of nonresponders. Therapy was well tolerated and produced a significant improvement in progressive-free survival. Further studies, thus, are recommended for larger groups of patients not only to confirm these results, but also to apply this biochemotherapy regimen as adjuvant postsurgical treatment in early stages of malignant melanoma.
Assuntos
Antineoplásicos Alquilantes/uso terapêutico , Fatores Imunológicos/uso terapêutico , Melanoma/tratamento farmacológico , Adulto , Idoso , Antineoplásicos Alquilantes/administração & dosagem , Terapia Combinada , Dacarbazina/administração & dosagem , Dacarbazina/uso terapêutico , Progressão da Doença , Esquema de Medicação , Feminino , Humanos , Fatores Imunológicos/administração & dosagem , Interferon-alfa/administração & dosagem , Interferon-alfa/uso terapêutico , Interleucina-2/administração & dosagem , Interleucina-2/uso terapêutico , Masculino , Melanoma/mortalidade , Pessoa de Meia-Idade , Metástase Neoplásica , Análise de SobrevidaRESUMO
Whether chronic ethanol ingestion significantly damages the small intestine remains controversial. To clarify this we have analysed the morphology of the small intestinal epithelium and quantified its renewal in chronically ethanol fed rats. Twenty adult male rats were pair fed for 28 days a nutritionally adequate liquid diet containing either ethanol as 36% of total calories or an isocaloric diet in which fat substituted for ethanol. Crypt cell production rate was determined in the jejunum and ileum by the metaphase arrest method. Weight gain and small intestinal morphology were similar in ethanol fed and control rats, but enterocyte turnover was significantly reduced in the jejunum (p less than 0.05) and ileum (p less than 0.01) of the ethanol fed rats. This effect of ethanol on the small intestine is probably systemic rather than local, because the changes in jejunum and ileum were similar, and it may contribute to the development of malnutrition in chronic alcoholics.
Assuntos
Etanol/farmacologia , Intestino Delgado/efeitos dos fármacos , Animais , Valva Ileocecal/citologia , Valva Ileocecal/efeitos dos fármacos , Intestino Delgado/citologia , Masculino , Metáfase , Piloro/citologia , Piloro/efeitos dos fármacos , Ratos , Ratos EndogâmicosRESUMO
The Authors after statistic elaborations about 6343 cases of impact tooth treated in Division of Odontostomatology and Maxillo-Face Surgery Regional Hospital "Umberto 1." of Ancona from 1974 to 1988 pay attention about the impact canine. They explay about the operative protocol that they divided in orthodontic and surgery times, emphatised the scrupulous execution of protocol to take a final success.
Assuntos
Dente Canino/patologia , Técnicas de Movimentação Dentária , Dente Impactado/cirurgia , Feminino , Humanos , Masculino , Aparelhos Ortodônticos , Retalhos CirúrgicosRESUMO
BACKGROUND: It has not been established whether the presence of intrinsic or acquired multiple drug-resistant (MDR) phenotype affects susceptibility to undergo iron-stimulated lipid peroxidation. EXPERIMENTAL DESIGN: To assess this point, human hepatocellular carcinoma cell lines with moderate, clinically relevant (P1) or elevated (P1(0.5)) MDR phenotype and their parental drug-sensitive (P5) cell line were exposed to ADP-Fe or ascorbate-Fe complexes and H2O2 in different experiments. Thiobarbituric acid-reactive substances (TBARS) were measured. Total cell glutathione, glutathione-S-transferase, total and selenium-dependent glutathione peroxidase activities, and cell alpha-tocopherol content were also determined. RESULTS: P5 and P1 cell lines showed similar and significant formation of TBAR after 1-hour incubation exposure to iron complexes, whereas P1(0.5) subclone did not. No accumulation of TBAR was observed during the exposure to H2O2 in the three cell lines. Among antioxidants, only alpha-tocopherol cell content was significantly higher in P1(0.5) in comparison with either P1 or P5. CONCLUSIONS: These data suggest that MDR phenotype development per se does not increase resistance to iron-related free radical attack in human hepatocellular carcinoma cell lines. Resistance to undergo lipid peroxidation is associated only to high degrees of drug resistance and appears more related to increased alpha-tocopherol cell content rather than an MDR phenotype.